Amid mixed movements between tech stocks and traditional blue-chip stocks in the U.S. market, Alteogen, the KOSDAQ's largest biotech company by market capitalization, posted a decline in the 6% range on Nextrade (NXT). The increased volatility is attributed to a combination of profit-taking demand accumulated during its recent upward trend and the possibility of shifts in supply and demand surrounding key upcoming events.

Falls Over 6% on the 28th... Drops to as Low as 288,000 Won During the Session

According to market data provided on the 28th, Alteogen closed at 293,000 won on NXT, down 19,000 won (6.09%) from the previous trading day. The previous day's base price was 312,000 won.

The stock opened at 313,000 won on this day and rose to 315,000 won in early trading. However, as sell orders flowed in afterward, it surrendered all of its gains, dropping to as low as 288,000 won at one point during the session. After hitting that low, it partially recovered its losses but failed to reclaim the 300,000-won level.

Trading volume reached 191,651 shares, with a traded value of 57.38 billion won. The gap between the intraday high and low was 27,000 won, indicating that investor trading direction shifted rapidly even within a single trading day.

Also a Burden on Overall KOSDAQ Biotech Investment Sentiment

With a market capitalization of approximately 15.88 trillion won, Alteogen ranks as the largest company on the KOSDAQ by market cap. Given its heavy weighting within the index and significant market influence, today's weakness is a trend that could burden not only Alteogen but also the broader investment sentiment for KOSDAQ biotech stocks.

Alteogen's competitive edge is based on its Hybrozyme technology, which converts intravenous biopharmaceuticals into subcutaneous injections. By utilizing its core substance, ALT-B4, the method enhances patient dosing convenience and reduces administration time at medical institutions. Technology transfer contracts with global pharmaceutical companies, progress in development stages, and the potential for commercialization have served as key criteria for evaluating the company's value.

Previously, the company decided to temporarily put on hold its plan to list on the main board and announced a 30% stock dividend (free share distribution).

U.S. Markets Mixed... Nasdaq Falls 0.85%, Growing Caution Toward AI Growth Stocks

In overseas markets, the New York Stock Exchange showed a mixed performance across its major indices. As of the afternoon of the 28th, Korean time, the Dow Jones Industrial Average rose 0.55%, while the S&P 500 index fell 0.15%. The Nasdaq Composite and the Russell 2000 index declined by 0.85% and 0.33%, respectively.

The Dow index gained on the strength of sectors with high earnings stability, such as consumer staples and healthcare. Conversely, the Nasdaq experienced selling pressure centered on the artificial intelligence and semiconductor sectors. As the need to verify the pace of revenue generation relative to massive AI investments grows stronger, caution toward highly valued growth stocks has increased.

It is difficult to definitively conclude that the U.S. market's movements on this day were directly reflected in Alteogen's stock price before the close of the domestic regular session, as the trading hours of the New York Stock Exchange and the domestic market differ. However, if the weakness in the Nasdaq and growth stocks persists, it could act as an external variable affecting domestic investment sentiment toward biotech and platform companies on the next trading day.

Short-Term Focus: Inflow of Buy Orders at NXT Lows and Maintaining the 290,000-Won Level

Key short-term indicators to watch for Alteogen's stock include whether buying interest emerges near the NXT intraday low of 288,000 won and whether it can maintain the 290,000-won level.

In the mid-to-long term, the development schedule for partner drugs based on ALT-B4 is more critical than daily stock price fluctuations. Investors will need to monitor global clinical trials and regulatory approval processes, product launch timelines, additional technology transfer agreements, and the reflection of milestone and royalty revenues in earnings.

In the U.S. market, the Federal Reserve's monetary policy, Treasury yields, and earnings from large-cap tech stocks are expected to act as variables that dictate risk appetite for growth stocks overall.

[This article is provided for investment reference purposes, and we are not responsible for investment decisions made based on it or their outcomes. This article was partially assisted by AI.]